REPLIMUNE GROUP
Replimune Group develop the next generation of ‘oncolytic immunotherapies’ for the treatment of cancer. Replimune is developing novel, proprietary products intended to improve both the direct anti-tumor effects of selective virus replication and the potency of the immune response to the tumor antigens released. The Company’s Immulytic™ platform is designed to maximize systemic immune activation, in particular to tumor neoantigens, through robust viral mediated immunogenic tumor cell kill... ing and the delivery of optimal combinations of immune activating proteins to the tumor and draining lymph nodes. The approach is expected to be highly synergistic with immune checkpoint blockade and other approaches to cancer treatment. Replimune intends to progress these therapies rapidly through clinical trials and to combine with other immuno-oncology products with complementary mechanisms of action at an early stage.
REPLIMUNE GROUP
Industry:
Biotechnology Health Care Medical Therapeutics
Founded:
2015-03-01
Address:
Woburn, Massachusetts, United States
Country:
United States
Website Url:
http://www.replimune.com
Total Employee:
101+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
87 M USD
Technology used in webpage:
SPF Google Font API LetsEncrypt Content Delivery Network Domain Not Resolving Microsoft Exchange Online Office 365 Mail IPv6 ReCAPTCHA JsDelivr
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Scholar Rock
Scholar Rock is a biopharmaceutical company that develops and discovers new medicines and treatments for the serious diseases.
Semma Therapeutics
Semma Therapeutics was founded to develop transformative therapies for Type 1 diabetes patients.
Slingshot Biosciences
Slingshot Biosciences develops next-generation synthetic cells for diagnostics and therapeutics.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Redmile Group
Redmile Group investment in Series B - Replimune Group
Atlas Venture
Atlas Venture investment in Series B - Replimune Group
Forbion Capital Partners
Forbion Capital Partners investment in Series B - Replimune Group
Cormorant Asset Management
Cormorant Asset Management investment in Series B - Replimune Group
Omega Funds
Omega Funds investment in Series B - Replimune Group
Bain Capital Life Sciences
Bain Capital Life Sciences investment in Series B - Replimune Group
Leerink Partners
Leerink Partners investment in Series B - Replimune Group
Foresite Capital
Foresite Capital investment in Series B - Replimune Group
Forbion Capital Partners
Forbion Capital Partners investment in Series A - Replimune Group
Atlas Venture
Atlas Venture investment in Series A - Replimune Group
Key Employee Changes
| Date | New article |
|---|---|
| 2019-12-10 | Replimune Taps Ex-Merrimack Exec for Chief Financial Officer Post |
Official Site Inspections
http://www.replimune.com Semrush global rank: 2.4 M Semrush visits lastest month: 7.63 K
- Host name: server2.stellarhosting.com
- IP address: 104.161.44.18
- Location: Phoenix United States
- Latitude: 33.4413
- Longitude: -112.0421
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85034
More informations about "Replimune Group"
Home - Replimune
2 days ago · Replimune’s mission is to revolutionize cancer treatment with therapies designed to activate a powerful and durable full-body anti-tumor response. We imagine a world where …See details»
Our Team - Replimune
Replimune has assembled a world-class leadership team who together pioneered the development of the first and only FDA-approved oncolytic immunotherapy.See details»
Replimune | Investor Relations
The Investor Relations website contains information about Replimune's business for stockholders, potential investors, and financial analysts.See details»
Replimune - LinkedIn
Replimune's mission is to revolutionize cancer treatment with therapies designed to activate a powerful and durable full-body anti-tumor response. Replimune is pioneering the development of...See details»
Replimune Group, Inc. - AnnualReports.com
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 to develop the next generation of oncolytic immune-gene therapies for the treatment of cancer.See details»
Replimune Group - Crunchbase Company Profile
Replimune Group develop the next generation of ‘oncolytic immunotherapies’ for the treatment of cancer. Replimune is developing novel, proprietary products intended to improve both the direct anti-tumor effects of selective virus …See details»
Medical Affairs - Replimune
Replimune is committed to supporting independent research to address areas of medical need and further investigate the safety/efficacy of our oncolytic immunotherapies. At Replimune, …See details»
Replimune Reports Fiscal Third Quarter 2024 Financial Results and ...
WOBURN, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of …See details»
Replimune Announces Positive Initial Data from the Anti-PD1 …
Dec 7, 2022 · IGNYTE is Replimune’s multi-cohort clinical trial evaluating RP1 combined with nivolumab in multiple tumor type specific cohorts. The Company is today presenting new data …See details»
Replimune Receives Breakthrough Therapy Designation for RP1 …
6 days ago · Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor …See details»
Replimune Announces Proposed Public Offering - Yahoo Finance
3 days ago · WOBURN, Mass., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel …See details»
Replimune Announces Pricing of Upsized Public Offering - Yahoo …
2 days ago · BOSTON, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic …See details»
Replimune Group Earns ‘Buy’ Rating on Strong Clinical Results and ...
Jun 10, 2024 · Replimune Group, Inc. is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through immulytic platform.See details»
Replimune Company Profile - Office Locations, Competitors, …
Oct 8, 2024 · Replimune is developing novel, proprietary oncolytic immunotherapies intended to improve both the direct anti-tumor effects of selective virus replication and the potency of the …See details»
Replimune: Strong Data In A Highly Differentiated Space - Seeking …
Sep 3, 2024 · Replimune's RP1, an oncolytic immuno-gene therapy, shows promise with a 31.4% ORR in phase 2 trials for post PD-1 melanoma and non-melanoma skin cancers. RP2, adding …See details»
Replimune: The Rise Of Oncolytic Virus Therapies In Cancer …
Replimune (NASDAQ: REPL) offers a compelling opportunity for investors seeking exposure to the rapidly growing field of oncolytic virus-based immunotherapy.See details»
Pipeline - Replimune
Replimune is advancing a novel pipeline of oncolytic immunotherapies derived from its RPx platform aimed to fill unmet need across cancer types. RPx therapies are engineered using a …See details»
Replimune Mission, Benefits, and Work Culture | Indeed.com
Come see what’s going on inside Replimune, including the company culture, employee work-life benefits, and business goals. Discover all the key insights that make people want to work …See details»
Pipeline - Replimune
Replimune is advancing a pipeline of tumor-directed oncolytic immunotherapies derived from its RPx platform to fill unmet need across cancer types. RPx therapies are engineered using a …See details»
Replimune: Oncolytic Immunotherapy Pioneer Gaining …
Apr 30, 2021 · Shares of oncolytic immunotherapy pioneer Replimune (NASDAQ: REPL) have risen by over 130% since my December 2019 ROTY recommendation was published. On the …See details»